慢性乙型肝炎:免疫学特征及当前临床试验中的治疗性疫苗
本综述总结治疗性疫苗接种的当前数据与未来展望,并讨论可与疫苗联合以实现HBV感染完全治愈的其他治疗选择。
要点
- 治疗性疫苗联合当前抗病毒药物及其他免疫调节策略可能对治疗CHB患者有用。
- 本综述总结治疗性疫苗接种的当前数据与未来展望,并讨论其他可联合疫苗的治疗选择。
核心结论
- 治疗性疫苗联合当前抗病毒药物及其他免疫调节策略可能对治疗CHB患者有用。
研究设计与样本
- 本综述总结治疗性疫苗接种的当前数据与未来展望,并讨论可与疫苗联合以实现HBV感染完全治愈的其他治疗选择。
主要发现
- 近年来,得益于临床前和临床研究,对克服慢性化所需免疫效应因子的认识显著增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
More than 250million people worldwide are chronically infected with hepatitis B virus (CHB), and over half a million die each year due to CHB-associated liver complications such as cirrhosis and hepatocellular carcinoma. The translation of immunological knowledge about CHB into therapeutic strategies aiming to a sustainable hepatitis B virus (HBV) clearance has been challenging. In recent years, however, the understanding on the immune effectors required to overcome chronicity has notably increased thanks to preclinical and clinical research. Therapeutic vaccination may prove to be useful for treating CHB patients when coupled with current antiviral agents and other immunomodulatory strategies. This review summarizes current data and future perspectives on therapeutic vaccination. Other treatment alternatives that could be combined with vaccines for a complete cure from hepatitis B virus infection are also discussed.
引用
- Lobaina Y, Michel ML. Chronic hepatitis B: Immunological profile and current therapeutic vaccines in clinical trials. Vaccine. 2017. PMID: 28351734. doi:10.1016/j.vaccine.2017.03.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。